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PERSPECTIVES ON DRUGS 
Comorbidity of substance use 
and mental health disorders  
in Europe
The association of harmful forms of illicit drug use with 
serious mental health problems is a key issue for national and 
international drug policy. The European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) refers to ‘comorbidity/
dual diagnosis’ as the ‘temporal coexistence of two or 
more psychiatric disorders as defined by the International 
Classification of Diseases, one of which is problematic 
substance use’ (EMCDDA, 2004). The relevance of the 
comorbidity of substance use and mental health disorders is 
related not only to its high prevalence but also to its difficult 
management and its association with poor outcomes for those 
affected. In comparison with patients with a single disorder, 
those with comorbid mental disorders and substance use 
disorders show a higher psychopathological severity (Langås 
et al., 2011; Stahler et al., 2009; Szerman et al., 2012) and 
increased rates of risky behaviour, which can lead to infection 
with diseases such as human immunodeficiency virus (HIV)/
acquired immune deficiency syndrome (AIDS) and hepatitis 
C virus (Khalsa et al., 2008), psychosocial impairments (e.g. 
unemployment, homelessness) and criminal behaviour 
(Greenberg and Rosenheck, 2014; Krausz et al., 2013). 
Taking into account the burden on health and legal systems, 
psychiatric comorbidity among people with substance use 
disorders leads to high costs for society (DeLorenze et al., 
2014; Whiteford et al., 2013).
I  Substance use and mental health disorders:  a complex relationship
The relationship between substance use and mental health 
disorders is complex and it is difficult to establish a clear 
Comorbidity of substance use and  
mental health disorders refers to the  
co-occurrence of a substance use disorder 
and another mental health disorder in the 
same individual. In Europe, the presence 
of psychiatric disorders associated with 
substance use disorders has become 
an important issue in drug policy and 
treatment provision. This is a result of 
the high prevalence of comorbidity, 
the complexity of treating it, and its 
association with poor treatment outcomes 
for those affected. This analysis explains 
what comorbidity is, its implications for 
care, types of service provision available 
in Europe and considers key issues for the 
future.  
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pathway between the two. The identification of psychiatric 
comorbidity is problematic, because the acute or chronic 
effects of substance abuse can mimic the symptoms of many 
other mental health disorders. Furthermore, a mental health 
disorder can have a negative impact on substance use (e.g. 
facilitate the start of substance use; increase the levels of 
drug use; facilitate risky patterns of drug use, etc.). Although 
convincing evidence supports a strong association between 
several mental health disorders and substance use disorders, 
the nature of this relationship may vary depending on the 
particular disorder (e.g. depression, psychosis, post-traumatic 
stress disorder) and the substance in question (e.g. alcohol, 
cannabis, opioids, stimulants). Overall, the coexistence of two 
or more clinical conditions in the same individual raises two 
major clinical questions:
1. Is there an underlying common causal pathway?
2. What is the impact of this coexistence of clinical conditions 
on clinical care?
I  Pathways to comorbidity
Below we list four (non-exclusive) hypotheses that can be 
used to explain comorbidity.
A. The substance use disorder and another mental health 
disorder may represent two or more independent conditions.
In this case, the combination may occur through chance 
alone or as a consequence of the same predisposing factors 
(e.g. stress, personality, childhood environment, genetic 
influences) that affect the risk for multiple conditions. That 
is, substance use disorders and other psychiatric disorders 
would represent different symptomatic expressions of similar 
pre-existing neurobiological abnormalities (Brady and Sinha, 
2005). Research in basic neuroscience has demonstrated the 
key roles of biological and genetic or epigenetic factors in an 
individual’s vulnerability to these disorders. But it has always 
to be considered that genes and neural bases are intimately 
interconnected with the environment.
B. The psychiatric disorder other than substance use disorder 
is a risk factor for drug use and the development of a 
comorbid substance use disorder.
In this scenario, different situations can be considered. In the 
‘self-medication hypothesis’ (Khantzian, 1985), the substance 
use disorder develops as a result of attempts by the patient 
to deal with problems associated with the mental health 
disorder (e.g. social phobia, post-traumatic stress disorder, 
psychosis). In this case, the substance use disorder might 
become a long-term problem, or the excessive use of alcohol 
or an illicit drug might abate when the pre-existing mental 
health disorder is addressed appropriately (Bizzarri et al., 
2009; Leeies et al., 2010; Smith and Randall, 2012). However, 
the psychiatric disorder could increase the risk of heavy and 
repetitive use of substances, leading to the development of 
a substance use disorder that might continue even when the 
pre-existing psychiatric condition is appropriately treated or 
remits (Moeller et al., 2001).
C. The substance use disorder could trigger the development 
of a psychiatric disorder in such a way that the additional 
disorder then runs an independent course.
Drug use can function as a trigger for an underlying long-term 
disorder. This is probably the most important mechanism 
underlying the association between cannabis use and 
schizophrenia. It is well known that cannabis use in vulnerable 
adolescents can facilitate the development of a psychosis that 
runs as an independent illness (Radhakrishnan et al., 2014).
D. The temporary psychiatric disorder is produced as a 
consequence of intoxication with, or withdrawal from, a 
specific type of substance, also called a substance-induced 
disorder.
Temporary psychiatric conditions (e.g. psychosis with 
features resembling schizophrenia) may be produced as a 
consequence of intoxication with specific types of substances 
(e.g. stimulants, such as amphetamines and cocaine) or 
withdrawal conditions (e.g. depressive syndromes associated 
with the cessation of stimulant use). The latest evidence of 
similar patterns of comorbidity and risk factors in individuals 
with substance-induced disorder and those with independent 
non-substance-induced psychiatric symptoms suggests 
that the two conditions may share underlying causal or 
aetiological factors (Blanco et al., 2012). Furthermore, there 
are some studies showing that, in some cases, previous 
induced disorders have been diagnosed as independent 
disorders after a follow-up period. These findings suggest that 
substance-induced disorders may be a transitory state prior 
to an independent disorder (Magidson et al., 2013; Martín-
Santos et al., 2010).
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I  Terms and definitions 
Defining comorbidity
The term ‘comorbidity of substance use and mental health 
disorders’ refers to the co-occurrence of a substance 
use disorder and another mental disorder in the same 
individual. Other terms used include ‘co-occurring 
disorder’, ‘comorbid disorder’ and ‘dual diagnosis’. The 
EMCDDA has defined ‘comorbidity’, in the context of 
drug users, as a ‘temporal coexistence of two or more 
psychiatric disorders as defined by the International 
Classification of Diseases, one of which is problematic 
substance use’ (EMCDDA, 2004). The World Health 
Organization (WHO) defines ‘dual diagnosis’ as ‘the 
co-occurrence in the same individual of a psychoactive 
substance use disorder and another psychiatric disorder’ 
(WHO, 2010). Since 2012, the World Psychiatric 
Association (WPA) has had a new section for this issue, 
and has chosen to use the term ‘dual disorders/pathology’ 
(WPA, 2014).
Estimating comorbidity prevalence
There is a relatively high prevalence of comorbidity in 
substance users, with about 50 % having both a substance 
use and mental health disorder (EMCDDA, 2015, p. 69). 
In the absence of any European epidemiological study 
on the comorbidity of mental health and substance use 
disorders, the existing epidemiological data come from 
national or local studies in the European countries. These 
studies differ in their respective definitions of comorbidity, 
methodologies used, substances considered, sampling 
procedures, and geographical particularities concerning 
treatment availability and drug markets. Consequently, the 
data should be interpreted with caution.
A comprehensive overview of existing epidemiological 
studies conducted in the European countries in the last 
decade is found in the EMCDDA Insights ‘Comorbidity 
of substance use and mental disorders in Europe‘. The 
table below presents data from selected studies on the 
prevalence of comorbidity of mental health and substance 
use disorders in different settings and populations in the 
European countries.
 
Data from selected studies of general populations and specific 
settings
Prevalence level
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7 % of the adult population meeting the diagnostic 
requirements of an anxiety disorder comorbid with a 
substance use disorder (study of the general population 
carried out in France between 1999 and 2003) (Leray et 
al., 2011). 
21 % of female students (mean age 22) with lifetime 
comorbidity when nicotine dependence was included in 
the substance use disorder (Spanish female university 
students) (Vázquez, 2011). 
D
ru
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Up to 90 % of mood disorders (sample of 150 patients 
from therapeutic communities in nine European countries) 
(De Wilde et al., 2007). 
Comorbidity (range for current Axis I and II disorders) 
from 42 % in drug outpatient to 58 % in a therapeutic 
community or detox unit (several Spanish studies using 
the same instrument for assessing psychiatric comorbidity 
— the PRISM). 
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Lifetime comorbidity in 1 208 psychiatric patients 
diagnosed with schizophrenia in three European countries: 
19 % in France, 21 % In Germany, 35 % in the United 
Kingdom (Carrà et al., 2012). 
P
ri
so
n
Psychiatric comorbidity figures vary from 21 % among 
male prisoners in Perugia (Italy) (Piselli et al., 2016) to 
approximately 85 % among drug-addicted prisoners in 
Asturias (Spain) (Casares López et al., 2011). 
H
om
el
es
s A follow-up study among 82 homeless people in Sweden 
found 74 % had a mental health disorder associated with 
misuse of alcohol and illicit drugs (Beijer et al., 2007). 
I  Comorbidity and clinical care
Effectively responding to the coexistence of substance use 
and mental health disorders represents a challenge for 
treatment services in several ways. Among the issues that 
make treatment complicated are those surrounding the 
assessment of clients, the types of combination treatments 
they require, and the specific context and settings within 
which services are provided to them.
I  Clinical assessment
Clinical assessment with the detection and diagnosis of the 
two symptoms is a fundamental requirement to increase the 
possibility of positive treatment outcomes of people suffering 
from psychiatric comorbidity. However, the complex link 
between mental health and substance use disorders can 
make the clinical diagnosis of comorbidity difficult. Principally, 
this challenge revolves around distinguishing between the 
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Specific characteristics of comorbid mental health and substance use disorders and clinical recommendations
Depression + substance use disorders Psychosis + substance use disorders
Description
People with major depression show a higher vulnerability to develop 
substance use disorder; and substance users are at higher risk of 
developing major depression.
The two conditions reinforce each other in a negative way: worse 
treatment outcomes, higher risk of suicide, greater need for healthcare.
Clinical recommendations
Treatment must be provided at the same time for both depression and 
substance use disorder, and ideally in an integrated system.
Selective serotonin reuptake inhibitors are not efficacious in treating 
mental health disorders where comorbid substance use disorders are 
also present.
Cognitive behavioural therapy (CBT) may help in some cases.
Pharmacological and psychosocial treatments for depression and 
substance use disorders 
Antidepressant and psychosocial treatments were analysed in a 
comprehensive review (EMCDDA, 2015) which found that: 
– Antidepressants have little effect on the maintenance of abstinence. 
When an antidepressant is effective in treating acute depression, there is 
only a relative reduction in the use of the psychoactive substance. 
– The impact of different psychotherapies, such as CBT, twelve-step 
facilitation and motivational interviewing, on major depression or on 
substance use disorders alone has been investigated without reaching a 
conclusive result.
Description
Substances can precipitate a psychotic disorder in predisposed 
individuals.
Some people have an underlying psychotic disorder that is exacerbated 
by concurrent use of substances.
People can experience an acute psychotic episode in response to 
substance intoxication or withdrawal.
The most common types of psychosis in substance users are 
schizophrenia and bipolar disorder.
Clinical recommendations
Guidelines are available for the use of antipsychotic drugs, but certain 
considerations must be taken into account: 
– The level and type of substance misuse should be recorded. 
– The patient should be warned about potential interactions between 
substances of misuse and prescribed medication.
Integrated treatment for psychosis and substance use disorders 
Integrated treatment of psychosis and substance use disorders (i.e. 
combining psychological and antipsychotic treatments) was found in a 
comprehensive review (EMCDDA, 2015) to be: 
– effective in significantly improving psychotic symptoms and substance 
use.
four causal or aetiological and neurobiological pathways into 
comorbidity discussed above. A number of instruments are 
used, with the main distinction being between screening 
and diagnostic instruments. Screening instruments are 
instruments that can be administered by an interviewer 
after a short training session, and which determine the 
initial needs for further follow-up on patients´ disorders or 
symptoms, and/or provide an early indication of psychiatric 
comorbidity. Diagnostic instruments are more in-depth 
and longer instruments, usually administered by expert 
professionals with a deeper knowledge of psychopathology. 
The choice of instrument will depend on the context (clinical, 
epidemiological, research), the assessment objectives (single 
or multiple diagnosis), the time available to conduct the 
assessment and the expertise of staff.
I Specific combinations and clinical recommendations
The association between mental health and substance use 
disorders has different characteristics depending upon the 
specific combinations of the two disorders.
The specific clinical aspects of the more common 
combinations of psychiatric comorbidity include mood, 
anxiety, psychotic, attention deficit and hyperactivity, eating 
and personality disorders. Psychiatric comorbidity has an 
impact on the clinical severity, psychosocial functioning 
and quality of life of patients with substance use disorders. 
The therapeutic approach to tackle dual diagnosis, whether 
pharmacological, psychological or both, has to take into 
account both disorders from diagnosis in order to choose 
the best option for each individual. Optimal management 
requires a good understanding of the efficacy, interactions 
and side effects of pharmacological and psychological 
treatments. The clinical aspects and corresponding treatment 
recommendations of the most common combinations of 
different types of substance use and mental health disorders 
are presented in Table below.
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Anxiety + substance use disorders Personality disorders + substance use disorders
Description
There are complex associations between the two disorders: 
– Substances may be used for self-medication in case of anxiety. 
– Anxiety can be the result of intoxication or withdrawal.
Clinical recommendations
Little research exists on effective treatment in this case.
Psychological interventions have shown a positive effect, though are 
insufficient if used alone.
Integrated treatment for anxiety and opioid disorders 
Combining CBT with antidepressants was found in a comprehensive 
review (EMCDDA 2015) to be: 
– effective in improving the outcomes for comorbid opioid and anxiety 
disorders patients.
Description
People with a personality disorder have more problematic symptoms 
of substance use disorders than those without a personality disorder.
Antisocial and borderline are the more frequent personality disorders 
in illicit drug users.
They are likely to participate in risky behaviours (sharing injecting 
equipment, risky sexual practices).
They have more difficulties in remaining in, and compliance with, 
treatment.
Clinical recommendations
These patients should be offered the same range of treatment options as 
other patients. 
As high-risk behaviour may persist, they should also be given treatment 
aimed at ameliorating the impact of the personality disorder.
Pharmacological treatments for personality and substance use 
disorders 
A comprehensive review (EMCDDA, 2015) found that: 
– there is no evidence that any pharmacotherapy is particularly beneficial 
in the comorbidity of personality disorders with substance use disorders.
ADHD + substance use disorders Eating + substance use disorders
Description
There has been increasing interest in attention deficit hyperactivity 
disorder (ADHD) and substance use.
Comorbidity patterns differ between two subtypes: attention deficit 
and hyperactivity disorders.
Clinical recommendations
Prescription of stimulants for ADHD is common.
There is no evidence that prescribed stimulants predispose people to 
future substance use, but misuse potential or non-compliance should be 
considered.
Pharmacotherapies should be evaluated. 
 
Pharmacological treatment of ADHD and substance use disorders 
Pharmacological treatment of ADHD was found in a systematic review 
with meta-analysis (Cunill et al., 2015, 13 studies, N = 1271) to have: 
– no effect in reducing substance use or improving retention in 
treatment, although the results found a small to moderate reduction of 
ADHD symptoms. 
Description
Strong evidence demonstrates that eating disorders and substance 
use disorders tend to co-occur.
Clinical recommendations
Recommended interventions of psycho-education on: aetiological 
commonalities, risks and sequelae of concurrent eating disorder 
behaviours and substance abuse.
Necessary to build a collaborative therapeutic relationship.
Dialectical behavioural therapy for this comorbid condition has proved to 
be effective.
Behavioural therapy for eating and substance use disorders 
Dialectical behavioural therapy was found in a comprehensive review 
(EMCDDA. 2015) to be: 
– effective in reducing both eating disorders and substance use 
disorders.
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I  Treatment services and implementation in European countries
Although specific clinical recommendations have been 
identified for most combinations of substance use and 
mental health disorder, there is broad agreement in the 
scientific literature that the two disorders should be 
addressed simultaneously and with a multidisciplinary 
approach, involving drug and mental health professionals 
working together towards common goals. However, there 
is still a lack of consensus regarding the most appropriate 
treatment setting and the most adequate pharmacological 
and psychosocial strategies. This has negative consequences 
for the patients, who encounter difficulties in identifying and 
accessing the best treatment for their disorders.
Three models of services have been implemented in Europe to 
date:
1) The sequential model
In this model, the psychiatric and substance disorders are 
treated consecutively and there is little communication 
between services. Patients usually receive treatment for 
the most serious problems first, and, once this treatment 
is completed they are treated for their other problems. In 
this model the patient may be passed between services, 
increasing the risk of dropout and relapse from both services. 
For that reason evidence suggests that this model should be 
avoided when dealing with dual diagnosis patients.
2) The parallel model
In this model, treatment of the two different disorders is 
undertaken at the same time, with drug and mental health 
services liaising to provide services concurrently. Although 
some level of coordination between the two systems may 
be achieved, the two treatment needs are often met with 
different therapeutic approaches and the medical model of 
psychiatry may conflict with the psychosocial orientation of 
drug services. A potential negative consequence of this model 
is the lack of overall coherence of the treatment plan, which 
often falls on the patient.
3) The integrated model
In this model, treatment is provided within a psychiatric 
or drug treatment service or a special comorbidity 
programme or service. Cross-referral to other agencies is 
avoided. Treatments include motivational and behavioural 
interventions, relapse prevention, pharmacotherapy and 
social approaches. Although integrated treatment has been 
promoted as a way of reducing the fragmentation, duplication 
and risk of ‘falling between the gaps’ that may arise from 
sequential or parallel treatment models, the evidence 
supporting this is limited and is usually based on non-
European approaches.
I  Conclusion
Psychiatric comorbidity is highly prevalent among substance 
users and is associated with increased levels of clinical and 
social severity. It has been associated with a poor prognosis 
of both psychiatric and substance use disorders and with 
fewer chances of recovery. At present there remains a lack of 
consensus regarding the most appropriate treatment settings 
and pharmacological and psychosocial strategies. This 
review notes that comorbid patients often have difficulties 
in accessing, and being coordinated within, required mental 
health and substance abuse services. The main barriers to 
the treatment are the separation of mental health and drug 
use treatment networks in most European countries, and the 
fact that treatment services may lack sufficient combined 
expertise to treat both types of disorders.
I  Interactive element: motion graphic
Video on psychiatric comorbidity available on the EMCDDA website:  
www.emcdda.europa.eu/topics/pods/comorbidity-substance-use-mental-
disorders-europe
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One of the most commonly used substances by 
individuals with psychosis is cannabis, and individuals with 
schizophrenia or bipolar disorder can receive an additional 
diagnosis of cannabis dependence (EMCDDA, 2015, p. 51). 
 
The associations between cannabis and psychosis can vary 
as follows: 
 
 Cannabis can induce or cause a temporary   
 psychotic state that clears within several days in  
 individuals with no prior diagnosis of psychosis. 
 Cannabis can trigger psychosis in individuals who  
 are at risk of psychosis. 
 Cannabis can worsen psychotic symptoms in  
 those individuals who have a current diagnosis of  
 psychosis. 
 
Furthermore, cannabis use is associated with an earlier 
onset of psychosis and an increasing inpatient readmission 
risk in first-episode psychotics. People with psychosis 
generally do not use cannabis in a self-medicating manner 
to reduce psychotic symptoms. Reported reasons for 
use include social isolation, lack of emotion or feeling 
for others, lack of energy, difficulty sleeping, depression, 
anxiety, agitation, tremors or shaking and boredom. These 
symptoms may occur as part of the psychotic illness or may 
be due to additional anxiety or depressive illnesses or to the 
side effects of medication. 
 
People with psychotic disorders should avoid cannabis and 
be counselled against its use. Brief interventions should be 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
offered for people with psychosis who may be using even 
small amounts of cannabis. In an acute psychotic episode 
caused by cannabis use, cessation of use will result in 
the resolution of the episode. Duration of cannabis use in 
people with bipolar disorder is associated with the duration 
of mania (EMCDDA, 2015, p. 51). 
 
Hall conducted a review of twenty years of research into 
the adverse effects of recreational cannabis use. Among 
the findings was that the risk of psychotic symptoms and 
disorders doubles if cannabis users started using the drug 
in their mid-teens and is amplified by having a personal or 
family history of psychotic disorders (Hall, 2015). 
 
Psychosis and cannabis use disorders
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